GlassScriptPhysician profile
Richard Paul Simons
NPI 1861454308
$13,932.56
in general payments reported to CMS, 2019-2025
31 companies · $8,729 in 2025
The $8,729 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,228 · 2020: $275 · 2021: $323 · 2022: $729 · 2023: $1,340 · 2024: $1,307 · 2025: $8,729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,800 · Food and Beverage: $4,172 · Travel and Lodging: $2,326 · Education: $77.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,800.00 |
| Food and Beverage | $4,172.22 |
| Travel and Lodging | $2,326.36 |
| Education | $77.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $7,907.27 | 2021-2025 | Azure Xt Dr Mri Surescan, Claria Mri Quad Crt-D Surescan, Micra |
| Novartis Pharmaceuticals Corporation | $976.81 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $734.61 | 2019-2025 | Brilinta, Farxiga, Lokelma |
| Amgen INC. | $607.00 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $475.81 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $334.01 | 2022-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $330.15 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $295.42 | 2019-2024 | Xarelto |
| Pfizer INC. | $275.53 | 2019-2025 | |
| Boston Scientific Corporation | $233.45 | 2019-2025 | Ekosonic, Eluvia |
| Kestra Medical Technology Services, INC. | $216.69 | 2022-2025 | Assure Wcd |
| Bayer Healthcare Pharmaceuticals INC. | $216.59 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.94 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $178.66 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Scpharmaceuticals INC. | $133.22 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $121.13 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $116.87 | 2023-2024 | Inpefa |
| Akcea Therapeutics, INC. | $93.34 | 2019 | |
| Esperion Therapeutics, INC. | $89.05 | 2022-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $67.19 | 2019 | |
| Alnylam Pharmaceuticals INC. | $56.55 | 2025 | |
| Irhythm Technologies, INC. | $53.97 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $44.79 | 2019-2024 | Evkeeza |
| Amarin Pharma, INC. | $41.80 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $27.81 | 2025 | Opsynvi |
| Shockwave Medical, INC | $21.45 | 2025 | |
| Abbott Laboratories | $18.53 | 2025 | Assurity |
| Tactile Systems Technology INC | $14.85 | 2024 | Entre Plus, Flexitouch Plus |
| Cardiovascular Systems INC. | $14.23 | 2019 | |
| Portola Pharmaceuticals, LLC | $13.10 | 2019 | |
| Bard Peripheral Vascular, INC. | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Simons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.